NGL Fine - Chem Share Price

NGL Fine Chem Limited, with its corporate operations in Mumbai, functions as a pharmaceutical manufacturing company in India. The company was incorporated in 1981 and is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health. NGL Fine Chem Limited produces Active Pharmaceutical Ingredients (APIs) and intermediates catering to the antiprotozoal and anthelmintic therapeutic segments, with its products used in the animal healthcare industry. The company operates its manufacturing plants located in Tarapur and Roha in Maharashtra and supplies its products across domestic and international markets.

NGL Fine Chem share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on API production volumes, raw material costs including various chemical intermediates, capacity utilization rates, export demand, and the performance of its veterinary API and human API segments. NGL Fine Chem stock price is influenced by various factors such as earnings, regulatory approvals from global health agencies, export registrations in target markets, changes in pharmaceutical manufacturing policies, and global API price trends. In the longer run, strategies such as expansion into new therapeutic categories, product portfolio diversification, development of complex multi-step organic synthesis capabilities, and value-added product development affect the stock market perceptions. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

NGL Fine Chem live share price provides real-time information about the last price traded, bid and ask prices, and trading volume. These indicators represent market activity and liquidity for this small-cap pharmaceutical stock, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the NGL Fine Chem live price helps in observing short-term price volatility and shows how a stock moves relative to the broader BSE Healthcare index. Furthermore, monitoring NGL Fine Chem stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

NGL Fine Chem Limited Company Fundamentals

a. Company Background

NGL Fine Chem Limited was incorporated on December 18, 1981 as a private limited company and later converted into a public limited company, with its registered office located in Mumbai, Maharashtra. The company is engaged in the manufacturing of pharmaceuticals and intermediates for usage in veterinary and human health. The company operates primarily in the pharmaceutical API segment, catering to the antiprotozoal and anthelmintic therapeutic segments. Its manufacturing operations are based in India, with major production facilities located in Tarapur and Roha in Maharashtra, while corporate functions are managed from its administrative office in Mumbai. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets. The company recently commissioned the first phase of operations at its Greenfield Project at S-18 Tarapur, with significant capital invested towards expansion work. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, global demand for veterinary APIs, regulatory requirements in export markets, input cost fluctuations, and the company’s focus on R&D in complex multi-step organic synthesis.

b. Company Product Lines

• Animal Health APIs form the core of the company’s business, with approximately 37 veterinary APIs catering to antiprotozoal and anthelmintic therapeutic segments for farm animals and mammals in the animal healthcare industry

• Human Health APIs complement the veterinary portfolio with 2 human pharmaceutical APIs manufactured for use in generic formulations

• Intermediates and Specialty Chemicals include approximately 4 chemical intermediates used as building blocks in the synthesis of finished pharmaceutical products

• Finished Dosage Forms include approximately 12 formulations in various categories including Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements

The product portfolio is structured to serve both domestic demand and select international markets.

c. Company Revenue Model

• Domestic API sales generate revenue through direct supply of veterinary and human health pharmaceutical ingredients to Indian formulation companies and domestic institutional buyers

• Export sales contribute from international customers across Europe, Asia Pacific, USA, and Rest of the World regions

• Contract Development and Manufacturing Organization (CDMO) services provide revenue through custom synthesis, process development, and manufacturing of generic APIs and intermediates for global pharmaceutical companies

• Finished dosage form sales contribute revenue through the sale of formulations in domestic markets

Revenue performance is primarily influenced by global demand for veterinary pharmaceutical ingredients, raw material costs, regulatory approvals for export markets, and selling price realizations in domestic and export markets.

d. Geographic Presence

• Manufacturing facilities located in Tarapur and Roha, Maharashtra, with a Greenfield Project at S-18 Tarapur commissioned in phases

• Corporate office situated in Mumbai, Maharashtra

• Domestic distribution network serves customers across India through direct supply channels

• Export markets include Europe, Asia Pacific, USA, and Rest of the World

e. Key Milestones

• 1981: Incorporation of the company on December 18

• 2025: Commissioned the first phase of operations at its Greenfield Project at S-18 Tarapur with significant capital capitalized in the books of accounts

• 2025: The company continued to focus on capacity expansions, product diversification, and strategic entries into high-growth segments

• 2025: Received rating revision from CRISIL with outlook revised to ‘Negative’ from ‘Stable’ while reaffirming the rating at ‘Crisil BBB+’

• Recent years: Continued focus on R&D in complex multi-step organic synthesis for the manufacture of generic APIs and intermediates

f. Industry Perspective

The API manufacturing industry is research-intensive and closely linked to demand from global formulation companies, generic drug manufacturers, and healthcare providers worldwide. Demand trends are influenced by chronic disease prevalence, patent expirations of blockbuster drugs, the growth of generic pharmaceutical markets, and increasing global healthcare access.

The industry is also affected by fluctuations in raw material prices such as chemical intermediates and solvents, along with energy and logistics costs. Regulatory compliance with quality standards from agencies like USFDA, WHO-GMP, and European authorities increasingly shapes production practices and capital investment decisions.

Companies in the sector must manage patent expirations, intense global competition from Chinese and Indian API manufacturers, pricing pressure from buyers, and regulatory compliance while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like NGL Fine Chem.

NGL Fine Chem Limited Stock Market Presence: Listings & Index Representation

NGL Fine Chem Limited is listed on the National Stock Exchange (NSE) under the symbol NGLFINE and on the Bombay Stock Exchange (BSE) with the scrip code 524774. NGL Fine Chem share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, NGL Fine Chem stock price is generally tracked by investors interested in the API manufacturing and veterinary pharmaceutical industry.

NGL Fine Chem Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap and BSE Healthcare indices. NGL Fine Chem share price finds representation in these indices based on its market standing. NGL Fine Chem stock price presence in these indices helps investors track the company relative to other API and veterinary pharmaceutical manufacturing companies.

NGL Fine Chem Limited Stock Performance and Share Price History

NGL Fine Chem share price today on the NSE reflects its position as a veterinary API and intermediate manufacturer serving both domestic and international markets across multiple regions. Its performance is qualitatively driven by factors such as production capacity utilization at its Tarapur and Roha facilities, management of raw material costs including chemical intermediates, growth in export sales to regulated markets, and the ability to maintain strict regulatory compliance with quality standards. Investors compare the NGL Fine Chem share price movement with other API manufacturing companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported NGL Fine Chem share price. Beyond operational and sector influences, corporate actions such as the company’s focus on expanding its CDMO capabilities and commissioning its new Greenfield project can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by global pharmaceutical demand and regulatory compliance for export markets.

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger export demand and stable production margins, whereas a significant low aligns with market corrections or sector volatility. NGL Fine Chem share price extremes reflect the impact of global pharmaceutical pricing policies, regulatory approvals from agencies, and earnings visibility, providing a framework for understanding historical performance.

NGL Fine Chem stock price behaviour mirrors the trading patterns of a small-cap pharmaceutical company within India’s API manufacturing ecosystem. The company’s diversified portfolio spanning veterinary APIS, intermediates, and finished dosage forms has shaped its price history. Over recent years, NGL Fine Chem share price has experienced periods of sharp gains in response to strong quarterly revenues and export order flows, followed by phases of consolidation as the company navigated margin pressures from raw material cost inflation. The stock has shown a certain level of volatility compared to the broader market, aligning with the cyclical nature of the API industry which is highly exposed to global price trends for veterinary medicines.

NGL Fine Chem share price performance has closely tracked global generic API demand and raw material cost cycles for chemical intermediates. Positive momentum appeared during the post-pandemic period, driven by increased global demand for generic veterinary medicines and favourable currency movements that boosted export realizations. However, periods of raw material cost inflation, intense competition from Chinese API manufacturers, and pricing pressure from buyers have led to consolidation in NGL Fine Chem share price. The company’s net profit has shown decline in the recent fiscal year, while quarterly revenues have indicated improving trends with net sales increasing year-on-year.

Despite market fluctuations and a recent rating outlook revision, NGL Fine Chem shares have reflected the company’s consistent capacity expansion and its growing CDMO presence. The company maintains a strong focus on R&D in complex multi-step organic synthesis, which positions it for long-term growth in the generic API space.

NGL Fine Chem share price has declined for several recurring reasons. A drop in global generic API demand or pricing pressure from formulation buyers directly impacts profitability and leads to selling pressure. Changes in government policy regarding API import restrictions or manufacturing quality standards can also cause NGL Fine Chem share price to fall. Moreover, increases in operational costs without matching price increases compress margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export order volumes, leading to price declines. The stock remains sensitive to raw material price movements and API pricing cycles, particularly given that more than 80% of the company’s business consists of exports. Broader market sell-offs in small-cap stocks also pull NGL Fine Chem share price down, regardless of the company’s individual performance. Delays in regulatory approvals for new export markets or product registrations can also weigh on investor sentiment, resulting in lower valuation.

NGL Fine Chem Limited Investor Relevance and Role in Portfolio

NGL Fine Chem Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to veterinary API manufacturing, CDMO services, and pharmaceutical intermediates. Its inclusion in healthcare indices underscores its importance in India’s veterinary pharmaceutical ingredient manufacturing space. The company’s strong export focus, its portfolio of approximately 39 APIs across multiple therapeutic categories, its CDMO capabilities, and its focus on R&D in complex multi-step organic synthesis make it a consideration for long-term allocations.

NGL Fine Chem share price receives influence from the company’s ownership structure. NGL Fine Chem equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of 72.74% of the company’s total shares, reflecting strong internal control with no pledge of promoter shares. Domestic institutional investors (DIIs) currently hold no stake in the company. Public shareholders hold the remaining 27.26% of the company’s shares, representing a significant retail shareholder base. This investor base, with stable promoter participation and no institutional debt on promoter holdings, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on API and veterinary pharmaceutical manufacturing.

Beyond fundamentals and ownership, the stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on raw material prices, export orders for veterinary APIs, and regulatory policy actions. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical ingredient sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in API import regulations or manufacturing quality standards.

Technical indicators provide additional insight into short-term momentum shifts in NGL Fine Chem stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader healthcare and small-cap sector trends. The company’s debt levels reflect a low use of leverage, with a total debt to equity ratio of 0.27. Return on equity (ROE) is at 6.69% and return on capital employed (ROCE) stands at 8.29%, and the company’s book value per share serves as a reference point for valuation.

Overall, NGL Fine Chem demonstrates a certain volatility profile compared to the broader market, with the stock generally considered to have moderate systematic risk. This makes it responsive to broader market movements and sector-specific factors such as raw material price fluctuations, regulatory approvals, and global API demand cycles.

NGL Fine Chem Limited Sectoral Relevance and Peer Positioning

NGL Fine Chem Limited sector relevance stems from its over four-decade presence in the API manufacturing industry since 1981, its position as a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health, its portfolio of approximately 39 APIs (37 veterinary, 2 human), intermediates and finished dosage forms in categories including Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements, its operations as a CDMO specializing in multi-stage organic synthesis of generic APIs, its two manufacturing facilities located in Tarapur and Roha in Maharashtra, its Greenfield project at S-18 Tarapur, and its strong export presence across Europe, Asia Pacific, USA, and other international markets, establishing it as a focused small-cap API provider supporting India’s veterinary pharmaceutical and global generic drug ecosystem. Peer comparisons with companies like Sequent Scientific, Hester Biosciences, Parenteral Drugs, and other API-focused pharmaceutical companies focus on regulatory certifications, product mix, export intensity, and value-added API diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API molecule pricing, global generic drug demand trends, and government pharmaceutical manufacturing policies further highlights NGL Fine Chem positioning within India’s broader API manufacturing market.

NGL Fine Chem market cap highlights its position as a small-cap player within India’s API and veterinary pharmaceutical sector. Based on recent data, the company’s market capitalization has experienced significant movement. The market cap has moved in line with investor perceptions of the company’s growth potential following its commissioning of the Greenfield project and its focus on expanding CDMO capabilities. From earlier years through more recent periods, NGL Fine Chem market cap showed an increasing trend as the company expanded its manufacturing capacity and diversified its API product pipeline, followed by phases of consolidation due to margin pressures and competitive intensity. This pattern reflects investor confidence during favourable generic drug cycles with strong demand for affordable veterinary medicines, followed by contraction during challenging periods impacted by intense competition from Chinese API manufacturers and rising input costs. This decrease mirrors the correction in the share price from its annual high to recent levels.

NGL Fine Chem earnings trajectory demonstrates the impact of its operational execution in a competitive global API industry. In recent fiscal years, total income showed trends supported by the core API manufacturing business. Based on available data, the company’s revenue from operations increased from previous fiscal periods to more recent periods, with net sales growth to Rs. 359.29 Crore in the latest fiscal year. However, profit after tax has shown a decline from Rs. 38.52 Crore to Rs. 18.13 Crore over the same period, reflecting the impact of margin pressures. Quarterly performance has shown sequential improvement in certain periods, with net sales in recent quarters rising compared to previous quarters and also compared to corresponding quarters of prior years, while net profit has shown mixed trends with profits in most quarters. The company’s export sales remain a key driver of business, with more than 80% of total business contributed by exports. NGL Fine Chem earnings have faced headwinds from fluctuating raw material costs, competitive pressures from international API producers, and pricing pressure from buyers. However, the company has expanded its API product portfolio and CDMO services to strengthen its market position, and expects growth from capacity expansions and strategic entries into high-growth segments. These developments illustrate the cyclical nature of the API manufacturing industry and the company’s position within this sector.

NGL Fine Chem EPS provides insight into its operational performance and income generation from API sales, chemical intermediates, and CDMO services. The company reported basic EPS of Rs. 29.35 in the latest fiscal year, compared to a stronger basic EPS of Rs. 62.34 in a prior year, showing the variability in API earnings due to margin pressures. However, trailing twelve-month EPS has shown improvement in recent quarters, with the company reporting net profit increases in certain quarters. NGL Fine Chem EPS for recent full fiscal years showed patterns compared to prior fiscal years, reflecting the impact of demand cycles, regulatory approvals, and cost structures. The company has a face value of Rs. 5 per share. More recent quarterly performance suggests that EPS has shown movement as the company benefits from operational optimization, improved product mix, and expansion into higher-value API segments.

NGL Fine Chem P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API sales, chemical intermediates, and CDMO services. Based on available data, the current P/E ratio stands at 37.97, compared to the industry average. The company’s profit after tax has shown patterns from previous fiscal years to the most recent fiscal year, with a significant decline in profitability impacting earnings multiple. Quarterly performance has demonstrated mixed movement, with profit after tax showing variability from earlier quarters to later quarters, accompanied by movement in total income on a quarter-on-quarter basis. NGL Fine Chem P/E ratio reflects how market sentiment evolves alongside the company’s operational performance in a competitive global industry. The company’s earnings before interest and taxes for recent quarters stood at levels reflecting operating efficiency impacted by market conditions. The net profit margin has shown movement in recent quarters compared to same quarters of prior years, indicating how the company manages cost structures and pricing power in a competitive API market.

Summary

NGL Fine Chem Limited operates as a small-cap API and veterinary pharmaceutical ingredient manufacturer with a history spanning over four decades. NGL Fine Chem share price gets influenced by global demand for generic veterinary APIs, raw material costs, regulatory approvals, and the company’s export performance across Europe, Asia Pacific, and the USA. The company’s strong portfolio of APIs, its CDMO capabilities, and its focus on R&D in complex multi-step organic synthesis support its market position. NGL Fine Chem stock price reflects operational execution within the competitive API manufacturing sector. The ownership structure shows stable promoter holding of 72.74% with no institutional participation and a significant retail minority.